



Step Therapy Criteria
2026 MCOE
Last Updated: 4/1/2026

BAFIERTAM THERAPY - UHCMR

Products Affected

- Bafiertam

Details

| Criteria | |
|-----------------|--|
| | Step 1: Generic dimethyl fumarate-containing product. Step 2: Bafiertam. |

DULOXETINE THERAPY - UHCMR

Products Affected

- Drizalma Sprinkle

Details

| | |
|-----------------|---|
| Criteria | Step 1: Formulary, generic duloxetine. Step 2: Drizalma. Approve for continuation of prior therapy. |
|-----------------|---|

FANAPT THERAPY - UHCMR

Products Affected

- Fanapt
- Fanapt Titration Pack A
- Fanapt Titration Pack B
- Fanapt Titration Pack C

Details

| | |
|-----------------|---|
| Criteria | Step 1: Two of the following oral, single-ingredient, formulary, generic atypical antipsychotics: asenapine, aripiprazole, paliperidone, olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Fanapt. Approve for continuation of prior therapy. |
|-----------------|---|

RHO KINASE INHIBITOR THERAPY - UHCMR

Products Affected

- Rhopressa
- Rocklatan

Details

| | |
|-----------------|---|
| Criteria | Step 1: Lumigan or generic latanoprost. Step 2: Rhopressa, Rocklatan. |
|-----------------|---|

RIVASTIGMINE PATCH THERAPY - UHCMR

Products Affected

- Rivastigmine Transdermal System

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic, oral rivastigmine capsule. Step 2: Generic rivastigmine transdermal systems |
|-----------------|--|

SECUADO THERAPY - UHCMR

Products Affected

- Secuado

Details

| | |
|-----------------|--|
| Criteria | Step 1: Two of the following oral, single-ingredient, formulary, generic atypical antipsychotics: asenapine, aripiprazole, paliperidone, olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Secuado. Approve for continuation of prior therapy. |
|-----------------|--|

SNRI THERAPY

Products Affected

- Fetzima
- Fetzima Titration Pack

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic venlafaxine extended release capsules. Step 2: Fetzima. Approve for continuation of prior therapy. |
|-----------------|--|

TOPICAL IMMUNOMODULATOR THERAPY

Products Affected

- Pimecrolimus
- Tacrolimus OINT

Details

| | |
|-----------------|--|
| Criteria | Step 1: Any two of the following formulary topical agents: desonide ointment, hydrocortisone 2.5% cream, hydrocortisone 2.5% ointment, generic aug betamethasone 0.05%, fluocinonide 0.05%. Step 2: Generic pimecrolimus, generic tacrolimus topical |
|-----------------|--|

UCERIS ORAL THERAPY - UHCMR

Products Affected

- Budesonide Er

Details

| | |
|-----------------|---|
| Criteria | Step 1: Generic mesalamine capsule 0.375g or generic mesalamine 1.2g, AND generic sulfasalazine. Step 2: Generic budesonide ER tablet |
|-----------------|---|

ULORIC THERAPY - UHCMR

Products Affected

- Febuxostat

Details

| | |
|-----------------|---|
| Criteria | Step 1: Oral, generic allopurinol. Step 2: Generic febuxostat |
|-----------------|---|

ZONISADE SUSPENSION THERAPY

Products Affected

- Zonisade

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic zonisamide capsule. Step 2: Zonisade suspension. Approve for continuation of prior therapy. |
|-----------------|--|

Plans are insured through UnitedHealthcare Insurance Company or one of its affiliated companies, a Medicare Advantage organization with a Medicare contract and a Medicare-approved Part D sponsor. Enrollment in the plan depends on the plan's contract renewal with Medicare.

[<OVEX3386716_000>]

Formulary ID# 00026002

Y0066_130404_093413 CMS Approved